Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles

被引:12
|
作者
Balayla, Jacques [1 ]
Tulandi, Togas [1 ]
Buckett, William [1 ]
Holzer, Hananel [1 ,2 ]
Steiner, Naama [1 ]
Shrem, Guy [1 ]
Volodarsky-Perel, Alexander [1 ,3 ]
机构
[1] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada
[2] Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel
[3] Jewish Gen Hosp, Lady Davis Res Inst, 3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada
关键词
Triple-negative breast cancer; Fertility preservation; Number of oocytes; Estrogen receptor; Progesterone receptor; EMBRYO-TRANSFER; LIVE BIRTH; WOMEN; ESTROGEN; TAMOXIFEN; ASSOCIATION; EXPRESSION; MUTATIONS; FEATURES; IMPACT;
D O I
10.1007/s10815-020-01730-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To evaluate fertility preservation outcomes in breast cancer women with different hormonal receptor profiles before oncological treatment. Methods The study population included women with a diagnosis of breast cancer who underwent fertility preservation from 2009 until 2018 at a university-affiliated tertiary hospital. Stimulation parameters and fertility preservation outcomes were compared among the following receptor-specific profile groups: (1) estrogen receptor positive (ER+) versus estrogen receptor negative (ER-), (2) triple-negative breast cancer (TNBC) versus estrogen and progesterone receptor positive (ER+/PR+), and (3) TNBC versus non-TNBC. Primary outcome was the total number of mature oocytes. Secondary outcomes included the number of retrieved oocytes, the peak estradiol level, and the number of follicles > 14 mm on the final oocyte maturation trigger day. Results A total of 155 cycles were included in the final analysis. These were divided into the exposure groups of ER+ (n = 97), ER- (n = 58), ER+/PR+ (n = 85), TNBC (n = 57), and non-TNBC (n = 98). Cycle outcomes revealed similar number of retrieved oocytes and follicles > 14 mm on the trigger day. Women with TNBC had significantly lower number of mature oocytes compared with those with ER + PR+ (7 (5-11) versus 9 (7-15); p = 0.02) and non-TNBC (7 (5-11) versus 9 (7-16); p = 0.01) status. Triple-negative breast cancer profile was associated with a significant reduction in the chance of developing over 10 mature oocytes (OR 0.41; 95% CI 0.19-0.92). Conclusion Among the different hormonal receptor profiles in breast cancer, the TNBC subtype has a negative effect on fertility preservation outcomes.
引用
收藏
页码:913 / 921
页数:9
相关论文
共 50 条
  • [21] Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients
    Michaan, Nadav
    Ben-David, Gila
    Ben-Yosef, Dalit
    Almog, Beni
    Many, Ariel
    Pauzner, David
    Lessing, Joseph B.
    Amit, Ami
    Azem, Foad
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2010, 149 (02) : 175 - 177
  • [22] Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation
    Kim, Sung Woo
    Kim, Tae Hee
    Han, Ji Yeon
    Kim, Seul Ki
    Lee, Jung Ryeol
    Jee, Ung Chul
    Suh, Chang Suk
    Kim, Seok Hyun
    GYNECOLOGICAL ENDOCRINOLOGY, 2022, 38 (03) : 227 - 230
  • [23] Long-term safety of controlled ovarian stimulation for fertility preservation before chemotherapy treatment in patients with breast cancer
    Shapira, Moran
    Sella, Tal
    Safrai, Myriam
    Villain, Evyatar
    Lifshitz, Dror
    Orvieto, Raoul
    Gal-Yam, Einav
    Meirow, Dror
    FERTILITY AND STERILITY, 2025, 123 (03) : 477 - 487
  • [24] Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response
    Alvarez, R. M.
    Ramanathan, P.
    HUMAN REPRODUCTION, 2018, 33 (11) : 2051 - 2059
  • [25] In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation
    Oktay, K.
    Buyuk, E.
    Rodriguez-Wallberg, K. A.
    Sahin, G.
    REPRODUCTIVE BIOMEDICINE ONLINE, 2010, 20 (05) : 634 - 638
  • [26] Fertility preservation in ovarian cancer patients
    Santos, Maria Luis
    Pais, Ana Sofia
    Almeida Santos, Teresa
    GYNECOLOGICAL ENDOCRINOLOGY, 2021, 37 (06) : 483 - 489
  • [27] Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients
    Shulman, Yael
    Almog, Benny
    Kalma, Yael
    Fouks, Yuval
    Azem, Foad
    Cohen, Yoni
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2021, 38 (03) : 743 - 750
  • [28] Fertility Counseling and Preservation for Breast Cancer Patients
    Dinas, Konstantinos D.
    DISEASES OF THE BREAST DURING PREGNANCY AND LACTATION, 2020, 1252 : 181 - 187
  • [29] Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols
    Balkenende, Eva M. E.
    Dahhan, Taghride
    Beerendonk, Catharina C. M.
    Fleischer, Kathrin
    Stoop, Dominic
    Bos, Annelies M. E.
    Lambalk, Cornelis B.
    Schats, Roel
    Smeenk, Jesper M. J.
    Louwe, Leonie A.
    Cantineau, Astrid E. P.
    de Bruin, Jan Peter
    Linn, Sabine C.
    van der Veen, Fulco
    van Wely, Madelon
    Goddijn, Mariette
    HUMAN REPRODUCTION, 2022, 37 (08) : 1786 - 1794
  • [30] Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer
    Oktay, Kutluk
    Turan, Volkan
    Bedoschi, Giuliano
    Pacheco, Fernanda S.
    Moy, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (22) : 2424 - U25